DailyIQ
|
Sector:Consumer DefensiveAll sectors
Last updated 1 hour ago

MO·Altria Group, Inc.

$.
+. (+.%)
After Hours
High
$75.28
Open
$74.08
Market Cap
123.25B
52W High
$75.28
Low
$73.17
P. Close
$74.21
P/E
15.31
52W Low
$54.70
Fwd P/E
50.09
DailyIQ Est.
$71.17
Technical Score (1D)
95
BUY
News Sentiment
74
BULLISH
Altria will host a live audio webcast on July 30, 2026 at 9 a.m. ET to present its Q2 and H1 2026 results, with the press release released at 7 a.m. ET beforehand. The webcast will provide the first opportunity for the CEO and CFO to explain revenue drivers, margin trends, and strategic initiatives, which could shape short‑term expectations for the company’s earnings and dividend policy. Investors should watch the webcast for any guidance on cigarette sales, the performance of the smoke‑free product mix, and potential share‑repurchase plans that could influence the company’s cash‑flow allocation. In parallel, the FDA has proposed a rule requiring foreign tobacco manufacturers to register facilities and disclose product listings, a measure that could raise compliance costs for overseas entrants and reduce competitive pressure on Altria. If the rule is finalized, Altria could benefit from a more favorable competitive landscape, potentially supporting its pricing power and dividend sustainability over the next ten trading days. Analyst attention to Altria has increased, with Zacks users tracking the stock more closely, reflecting growing interest in the upcoming earnings and regulatory developments that may affect the company’s shift toward alternative nicotine products. Despite a valuation discount indicated by DCF and market multiples, Altria’s high 5.83 % dividend yield and robust profitability suggest a solid income play, though the transition to smoke‑free products and regulatory risks could temper upside. UBS has raised its price target to $79 from $76 and maintains a Buy rating, signaling confidence in Altria’s earnings outlook and dividend resilience, but traders should monitor the final FDA rule and the company’s earnings guidance for confirmation. Overall, the combination of an imminent earnings webcast, potential regulatory tightening on foreign competition, and a bullish analyst stance creates a short‑term narrative that hinges on the company’s earnings performance and the FDA’s rule adoption, which should be closely watched over the next 1–10 trading days.
Earnings Summary
Altria Group, Inc. is a U.S. tobacco company that manufactures and distributes a broad portfolio of smokeable and oral tobacco products, including Marlboro cigarettes, Black & Mild cigars, and smokeless offerings such as Copenhagen and Skoal, as well as oral nicotine pouches and e‑vapor products, positioning it firmly within the consumer defensive tobacco sector. In the most recent reporting cycle, Altria’s Q4 2025 earnings per share (EPS) of $1.30 fell short of the $1.3575 estimate while revenue of $5.079 billion missed the $5.1905 billion forecast, reflecting a continued downward trend from the $5.106 billion Q4 2024 revenue; the preceding quarter, Q1 2026, saw EPS of $1.32 versus an estimate of $1.47231 and revenue of $4.758 billion against a $5.295 billion estimate, underscoring a persistent revenue decline and a modest EPS rebound relative to the prior year. Historically, Altria has delivered EPS that beat analyst expectations in four of the last five quarters (Q4 2024, Q1 2025, Q2 2025, Q3 2025) but has struggled to meet revenue targets in the same period, with Q4 2025 and Q1 2026 both missing estimates; this pattern suggests that while profitability remains resilient, revenue growth has been uneven, likely tied to shifting consumer preferences and regulatory pressures. Recent news highlights a strategic pivot toward smoke‑free and alternative nicotine products, with the company announcing new offerings beyond its traditional cigarettes and cigars, and analysts noting a valuation discount that could be offset by successful scaling of the smoke‑free segment; regulatory updates on flavored e‑cigarettes and non‑combustible nicotine products are also cited as material risks that could influence future earnings. Investors should watch the upcoming earnings guidance for explicit commentary on the mix of cigarette versus smoke‑free sales, the pace of product launches, and any regulatory developments that could alter the company’s growth trajectory, as these factors will be key to interpreting Altria’s revenue dynamics and EPS performance in the next quarter.

EPS

EstBeatMiss
$1.14$1.24$1.34$1.44$1.54Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.50 - -
Q1'26$1.47$1.32-10.3%
Q4'25$1.36$1.30-4.2%
Q3'25$1.45$1.45+0.1%
Q2'25$1.38$1.44+4.0%
Q1'25$1.19$1.23+3.5%

Revenue

EstBeatMiss
$4.4B$4.7B$5.0B$5.3B$5.7BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$5.5B - -
Q1'26$5.3B$4.8B-10.1%
Q4'25$5.2B$5.1B-2.1%
Q3'25 - $5.3B -
Q2'25 - $5.3B -
Q1'25 - $4.5B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

MO Stock Snapshot

MO is currently trading at $74.98, giving Altria Group, Inc. a market cap of 123.25B and a P/E ratio of 15.3. Today's range spans $73.17–$75.28, with shares opening at $74.08 and moving up $0.77 (1.0%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY) with a news sentiment reading of 74/100.

Over the past year MO has traded between $54.70 and $75.28 - the current price is +37.1% off the 52-week low and -0.4% from the high. 23 analysts cover the stock with a Hold consensus and a mean 12-month target of $70.64 (range $59.00–$82.00), implying downside of -5.8%.

The BUY technical setup for MO (95/100) is worth attention in the context of the broader Consumer Defensive sector. At $74.98 (near 52-week highs), with 123.25B in capitalization and bullish sentiment at 74/100 The current P/E ratio stands at 15.3., this large-cap name sits at the intersection where momentum strategies and fundamental growth investors both find something to like. Annual range: $54.70–$75.28.

What makes MO's BUY setup (95/100) particularly actionable at 123.25B in Consumer Defensive capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $74.98 (near 52-week highs in $54.70–$75.28), with sentiment running bullish at 74/100, the setup rewards conviction-sized positioning more than it does speculative small bets.